Health
Sinopharm shares phase 2 data on inactivated COVID-19 vaccine – FierceBiotech
Sinopharm has published clinical data on its adjuvanted SARS-CoV-2–inactivated virus vaccine. The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the pandemic coronavirus.
Sinopharm has published clinical data on its adjuvanted SARS-CoV-2inactivated virus vaccine. The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the pandemic coronavirus.
Most of the frontrunners in the COVID-19 vaccine race are using relatively unproven approaches to immunization. BioNTech, in partnership with Pfizer, and Moderna are advancing mRNA vaccines, a type of prophylactic that has never been approved. AstraZen…
-
Noosa News20 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Business22 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…
-
Noosa News21 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
General21 hours agoInternal Revenue Service starts cutting 20,000 workers